Harbour BioMed Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 167

Employees

  • Stock Symbol
  • 02142

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.21
  • (As of Monday Closing)

Harbour BioMed General Information

Description

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

Contact Information

Formerly Known As
HBM Holdings
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Corporate Office
  • Kwun Tong Road
  • Floor 5
  • Hong Kong, 348
  • Hong Kong

Harbour BioMed Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Harbour BioMed Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.21 $0.17 - $0.36 $151M 734M 2.43M -$0.09

Harbour BioMed Financials Summary

In Thousands,
USD
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 58,479 126,726 457,483 1,284,616
Revenue 54,025 40,659 4,308 14,107
EBITDA (54,770) (129,864) (133,113) (291,736)
Net Income (61,249) (137,222) (137,777) (296,397)
Total Assets 223,513 232,123 282,361 388,738
Total Debt 83,040 90,929 19,473 1,725
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Harbour BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiate
Drug Discovery
Hong Kong, Hong Kong
167 As of 2023
00000
0.000 0000-00-00
00000000 00000

0000 0

e dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Beijing, China
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

000 00

d minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000000000000
Shanghai, China
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Harbour BioMed Competitors (87)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Brii Biosciences Formerly VC-backed Beijing, China 000 00000 00000000 00000
Zai Lab Formerly VC-backed Shanghai, China 0000 00.000 00000000 00.000
Clover Biopharmaceuticals Formerly VC-backed Shanghai, China 000 00.000 000000000 00.000
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 0000000000.
Vertex Pharmaceuticals Formerly VC-backed Boston, MA 0000 00.000 000000&0
You’re viewing 5 of 87 competitors. Get the full list »

Harbour BioMed Patents

Harbour BioMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3228682-A1 Anti-b7-h4 antibody, and preparation method therefor and use thereof Pending 18-Aug-2021
US-20230134183-A1 Cldn18.2-targeting antibody, bispecific antibody and use thereof Pending 09-Aug-2021 000000000
CA-3228137-A1 Cldn18.2-targeting antibody, bispecific antibody and use thereof Pending 09-Aug-2021
AU-2022291982-A1 Bispecific antibody combination and use thereof Pending 18-Jun-2021
CA-3223103-A1 Bispecific antibody combination and use thereof Pending 18-Jun-2021
To view Harbour BioMed’s complete patent history, request access »

Harbour BioMed Executive Team (18)

Name Title Board Seat Contact Info
Yingying Chen Ph.D Chief Financial Officer
Amy Que Ph.D Chief Technology Officer
Xiaoxiang Chen MD Chief Development Officer
Yiping Rong Chief Scientific Officer
Xiaolu Tao Chief Development Officer
You’re viewing 5 of 18 executive team members. Get the full list »

Harbour BioMed Board Members (1)

Name Representing Role Since
Jingsong Wang Ph.D Self Founder, Chief Executive Officer & Chairman 000 0000
To view Harbour BioMed’s complete board members history, request access »

Harbour BioMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Harbour BioMed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Harbour Antibodies 19-Dec-2016 0000000000 Drug Discovery 00000000
HBM Alpha Joint Venture Biotechnology
To view Harbour BioMed’s complete investments and acquisitions history, request access »

Harbour BioMed Subsidiaries (1)

Company Name Industry Location Founded
Harbour Antibodies Drug Discovery 0000
To view Harbour BioMed’s complete subsidiaries history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »